Invitae Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Şu anda Invitae için büyüme ve gelir tahmini yapmak üzere yeterli analist kapsamımız yok.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Healthcare kazanç büyümesi	19.9%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	None
Son güncelleme	n/a

Gelecekteki son büyüme güncellemeleri

Recent updates

Cautious Investors Not Rewarding Invitae Corporation's (NYSE:NVTA) Performance Completely

Dec 20

Invitae maintains 2022 financial guidance as Q2 results beat on top and bottom lines

Aug 09

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak Invitae yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

OTCPK:NVTA.Q - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
9/30/2023	482	-1,441	-248	-238	N/A
6/30/2023	494	-800	-319	-300	N/A
3/31/2023	510	-3,117	-414	-380	N/A
12/31/2022	516	-3,106	-546	-493	N/A
9/30/2022	520	-3,212	-654	-587	N/A
6/30/2022	501	-3,109	-695	-623	N/A
3/31/2022	481	-451	-687	-618	N/A
12/31/2021	460	-379	-615	-560	N/A
9/30/2021	435	-408	-542	-497	N/A
6/30/2021	389	-313	-427	-395	N/A
3/31/2021	319	-613	-351	-326	N/A
12/31/2020	280	-602	-321	-299	N/A
9/30/2020	245	-445	-253	-232	N/A
6/30/2020	233	-421	-229	-207	N/A
3/31/2020	241	-303	-200	-179	N/A
12/31/2019	217	-242	-165	-145	N/A
9/30/2019	196	-195	-129	-113	N/A
6/30/2019	177	-148	-106	-95	N/A
3/31/2019	161	-131	-95	-88	N/A
12/31/2018	148	-129	-98	-92	N/A
9/30/2018	128	-140	-115	-108	N/A
6/30/2018	109	-136	-121	-115	N/A
3/31/2018	86	-133	-116	-109	N/A
12/31/2017	68	-123	-105	-98	N/A
9/30/2017	52	-108	-92	-84	N/A
6/30/2017	40	-105	N/A	-76	N/A
3/31/2017	31	-102	N/A	-74	N/A
12/31/2016	25	-100	N/A	-76	N/A
9/30/2016	19	-100	N/A	-80	N/A
6/30/2016	15	-97	N/A	-85	N/A
3/31/2016	11	-97	N/A	-86	N/A
12/31/2015	8	-90	N/A	-81	N/A
9/30/2015	6	-81	N/A	-74	N/A
6/30/2015	4	-71	N/A	-62	N/A
3/31/2015	3	-57	N/A	-52	N/A
12/31/2014	2	-47	N/A	-42	N/A
9/30/2014	1	-40	N/A	-36	N/A
6/30/2014	1	-35	N/A	-34	N/A
3/31/2014	0	-29	N/A	-27	N/A
12/31/2013	0	-25	N/A	-23	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: NVTA.Q 'un tahmini kazanç büyümesinin tasarruf oranının ( 2.5% ) üzerinde olup olmadığını belirlemek için yeterli veri yok.

Kazançlar ve Piyasa: NVTA.Q 'un kazançlarının US pazarından daha hızlı büyümesinin öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Yüksek Büyüme Kazançları: NVTA.Q şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artıp artmayacağını belirlemek için yeterli veri bulunmuyor.

Gelir ve Pazar: NVTA.Q şirketinin gelirinin US pazarından daha hızlı büyüyeceğinin tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Yüksek Büyüme Geliri: NVTA.Q şirketinin gelirinin yıllık 20% oranından daha hızlı artacağının tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: NVTA.Q 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Invitae Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Invitae Corporation Provides Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2023

Price target decreased by 11% to US$1.31

Consensus EPS estimates fall by 119%

Invitae Corporation Reaffirms Earnings Guidance for the Full Year 2023

Price target increased by 30% to US$1.92

Price target decreased by 14% to US$1.58

Recent updates

Invitae Launches Unlock Behind the Seizure Program for Pediatric Epilepsy Patients

First Amended Disclosure Statement Approved for Invitae Corporation

Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Substantially all Assets of Invitae Corporation for approximately $240 million.

Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance

Invitae Launches Update to Invitae Generation: Clinical Variant Modeling Improves Variant Classification

Invitae Corporation Provides Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2023

Motion for Asset Sale Filed by Invitae Corporation

Invitae Corporation Filed for Bankruptcy

Invitae Corporation(OTCPK:NVTA) dropped from S&P TMI Index

The New York Stock Exchange to Commence Delisting Proceedings against Invitae

Invitae Corporation May File for Bankruptcy

New minor risk - Market cap size

Cautious Investors Not Rewarding Invitae Corporation's (NYSE:NVTA) Performance Completely

Invitae Corporation Announces Board Changes

Invitae Corporation Announces the Retirement of Robert L. Nussbaum as Chief Medical Officer, Effective December 29, 2023

Price target decreased by 11% to US$1.31

Invitae Corporation Appoints Ana J. Schrank as Chief Accounting Officer

Consensus EPS estimates fall by 119%

New major risk - Financial position

Invitae Corporation Reaffirms Earnings Guidance for the Full Year 2023

Price target increased by 30% to US$1.92

Third quarter 2023 earnings: EPS misses analyst expectations

Invitae Corporation to Report Q3, 2023 Results on Nov 08, 2023

Invitae Corporation Announces Findings from the Study to Date on Uncertain Results from Hereditary Disease Genetic Testing

Invitae Corporation Appoints David Sholehvar as Chief Operating Officer, Effective November 13, 2023

Price target decreased by 14% to US$1.58

Invitae Announces Results of Its Collaborative Study on Universal Hereditary Cancer Genetic Testing in All Patients with Breast Cancer in A Rural Population in the Annals of Surgical Oncology

Invitae Corporation Announces Change of Chief Financial Officer, Effective October 2, 2023

Invitae Receives Notice of Non-Compliance with NYSE Minimum Share Price Continued Listing Standard

Invitae Receives Notice of Non-Compliance with NYSE Minimum Share Price Continued Listing Standard

New major risk - Financial position

Invitae Corporation Announces Clinical Trial Results Support Genetic Testing of All Patients with Prostate Cancer

Price target decreased by 13% to US$1.70

Consensus EPS estimates fall by 34%

Invitae Corporation Provides Revenue Guidance for the Year 2023

Invitae Corporation Provides Revenue Guidance for the Year 2023

Price target decreased by 8.2% to US$1.87

Second quarter 2023 earnings: EPS misses analyst expectations

Invitae: Revenue Troubles Build

Invitae Corporation to Report Q2, 2023 Results on Aug 08, 2023

Invitae Is Treading In Competitive Waters

Invitae Corporation Announces Executive Changes

Invitae Corporation's (NYSE:NVTA) Prospects Need A Boost To Lift Shares

Invitae Corporation Announces Nine Studies to Be Presented At the 2023 American Society of Clinical Oncology Annual Meeting Reinforce the Critical Role of Germline Genetic Testing in Oncology

Invitae Announces CFO Changes

President recently sold US$54k worth of stock

Invitae Corporation Announces It Intends to Appeal the Verdict Delivered by A Jury At the United States District Court

Consensus EPS estimates fall by 19%

First quarter 2023 earnings: EPS misses analyst expectations

Price target decreased by 10.0% to US$2.26

Full year 2022 earnings: EPS misses analyst expectations

Invitae Corporation to Report Q4, 2022 Results on Feb 28, 2023

Price target decreased by 7.4% to US$2.51

Invitae Corporation Appoints William H. Osborne to its Board of Directors

Invitae: What Happened At The JP Morgan Health Conference

Invitae guides Q4 revenue above estimates

Director recently sold US$115k worth of stock

Invitae Likely Hasn't Reached The Bottom Yet

Invitae Releases Data Use Transparency Report, Demonstrating the Impact of Patient Data on Genetic Research

Invitae Launches Rare Patient Network for Pediatric Patients with Rare Neurodevelopmental Diseases

Consensus forecasts updated

Invitae: This Turnaround Could Be Painful

Invitae Corporation Reiterates Earnings Guidance for the Year 2022

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Invitae Corporation Reports Asset Impairments for the Third Quarter Ended September 30, 2022

Invitae GAAP EPS of -$1.27 misses by $0.43, revenue of $133.54M beats by $2.16M

Invitae Corporation Study Shows Therapy Informed by Genetic Testing Reduces Seizures in Some Patients with Epilepsy

Invitae Corporation to Report Q3, 2022 Results on Nov 08, 2022

Price target decreased to US$2.71